Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (unaudited)

v3.22.2
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (unaudited) - USD ($)
$ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
AOCI Attributable to Parent [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2020 $ 6 $ 355,237 $ (62) $ (267,533) $ 87,648
Balance, at beginning (in shares) at Dec. 31, 2020 6,568,335        
Issuance of common stock in exchange for exercise of warrants in March 2021 ($18.24 per share) 2 2
Issuance of common stock in exchange for exercise of warrants in March 2021 ($18.24 per share) (in shares) 107        
Issuance of common stock in January 2021 ($25.60 per share), net of transactional expenses of $3,096 $ 2 36,902 36,904
Issuance of common stock in January 2021 ($25.60 per share), net of transactional expenses of $3,096 (in shares) 1,562,500        
Issuance of common stock in February 2021 ($38.40 per share), net of transactional expenses of $5,002 $ 2 64,995 64,997
Issuance of common stock in February 2021 ($38.40 per share), net of transactional expenses of $5,002 (in shares) 1,822,917        
Issuance of common stock in January 2021 under At-the-market offering, net of transactional expenses of $230 6,779 6,779
Issuance of common stock in January 2021 under At-the-market offering, net of transactional expenses of $230 (in shares) 297,437        
Employee stock purchase plan 28 28
Employee stock purchase plan (in shares) 1,703        
Stock-based compensation 1,212 1,212
Foreign currency transaction gain (1) (1)
Net loss (20,653) (20,653)
Ending balance, value at Mar. 31, 2021 $ 10 465,155 (63) (288,186) 176,916
Balance, at end (in shares) at Mar. 31, 2021 10,252,999        
Beginning balance, value at Dec. 31, 2020 $ 6 355,237 (62) (267,533) 87,648
Balance, at beginning (in shares) at Dec. 31, 2020 6,568,335        
Foreign currency transaction gain         (9)
Net loss         (44,206)
Ending balance, value at Jun. 30, 2021 $ 11 492,292 (71) (311,739) 180,493
Balance, at end (in shares) at Jun. 30, 2021 10,954,279        
Beginning balance, value at Mar. 31, 2021 $ 10 465,155 (63) (288,186) 176,916
Balance, at beginning (in shares) at Mar. 31, 2021 10,252,999        
Issuance of common stock in April and June 2021 under At-the-market offering, net of transactional expenses of $612 $ 1 18,701 18,702
Issuance of common stock in April and June 2021 under At-the-market offering, net of transactional expenses of $612 (in shares) 489,332        
Issuance of commitment shares under 2021 Purchase Agreement
Issuance of commitment shares under 2021 Purchase Agreement (in shares) 40,000        
Issuance of common stock under 2021 Purchase Agreement 3,347 3,347
Issuance of common stock under 2021 Purchase agreement (in shares) 85,938        
Issuance of common stock in the acquisition of the OyaGen license 3,000 3,000
Issuance of common stock in the acquisition of the OyaGen license (in shares) 86,010        
Stock-based compensation 2,089 2,089
Foreign currency transaction gain (8) (8)
Net loss (23,553) (23,553)
Ending balance, value at Jun. 30, 2021 $ 11 492,292 (71) (311,739) 180,493
Balance, at end (in shares) at Jun. 30, 2021 10,954,279        
Beginning balance, value at Dec. 31, 2021 $ 16 578,613 (92) (359,820) 218,717
Balance, at beginning (in shares) at Dec. 31, 2021 15,638,274        
Issuance of common stock in January and March 2022 under At-the-market offering, net of transactional expenses of $507 $ 1 8,487 8,488
Issuance of common stock in January and March 2022 under At-the-market offering, net of transactional expenses of $507 (in shares) 1,076,661        
Issuance of common stock under 2021 Purchase Agreement $ 1 4,534 4,535
Issuance of common stock under 2021 Purchase agreement (in shares) 687,500        
Employee stock purchase plan 40 40
Employee stock purchase plan (in shares) 4,033        
Stock-based compensation 2,620 2,620
Foreign currency transaction gain (26) (26)
Net loss (26,417) (26,417)
Ending balance, value at Mar. 31, 2022 $ 18 594,294 (118) (386,237) 207,957
Balance, at end (in shares) at Mar. 31, 2022 17,406,468        
Beginning balance, value at Dec. 31, 2021 $ 16 578,613 (92) (359,820) 218,717
Balance, at beginning (in shares) at Dec. 31, 2021 15,638,274        
Foreign currency transaction gain         (51)
Net loss         (49,557)
Ending balance, value at Jun. 30, 2022 $ 32 637,770 (143) (409,377) 228,282
Balance, at end (in shares) at Jun. 30, 2022 31,692,024        
Beginning balance, value at Mar. 31, 2022 $ 18 594,294 (118) (386,237) 207,957
Balance, at beginning (in shares) at Mar. 31, 2022 17,406,468        
Issuance of common stock in April, May and June 2022 under At-the-market offering, net of transactional expenses of $1,426 $ 14 42,954 42,968
Issuance of common stock in April, May and June 2022 under At-the-market offering, net of transactional expenses of $1,426 (in shares) 13,879,306        
Issuance of common stock under 2021 Purchase Agreement 1,964 1,964
Issuance of common stock under 2021 Purchase agreement (in shares) 406,250        
Preferred stock deemed dividend (4,255) (4,255)
Stock-based compensation 2,813 2,813
Foreign currency transaction gain (25) (25)
Net loss (23,140) (23,140)
Ending balance, value at Jun. 30, 2022 $ 32 $ 637,770 $ (143) $ (409,377) $ 228,282
Balance, at end (in shares) at Jun. 30, 2022 31,692,024